Innoviva, Inc. (INVA)

Innoviva's stock price has increased significantly in the past six months. This rise was influenced by strong financial results for 2025, including revenue growth and net income exceeding expectations. The FDA approval of NUZOLVENCE and the successful U.S. launch of ZEVTERA also contributed positively. Additionally, the company initiated a share repurchase program. Broader market volatility has also influenced INVA's stock performance.

There is no specific data indicating significant demand seasonality for Innoviva's products and services. The company's revenue streams include consistent royalty payments and growing sales from its therapeutics, with no explicit seasonal patterns reported.

Innoviva, Inc. is a diversified healthcare holding company involved in the development, commercialization, and financial management of biopharmaceuticals. Its business model includes a core royalties portfolio, a critical care and infectious disease platform (Innoviva Specialty Therapeutics), and strategic healthcare investments. Major products include respiratory assets partnered with Glaxo Group Limited (GSK) and therapeutics marketed through its IST platform.

Innoviva operates in the United States and internationally, with its headquarters in Burlingame, California. A significant portion of its shareholders are based in the United States.

Innoviva has received positive recognition, including a strong performance rating from the Access to Medicine Foundation. Two of its products, ZEVTERA and XACDURO, were nominated for the Prix Galien USA Award for Best Pharmaceutical Product. No significant negative events impacting its brand reputation were found.

Innoviva is a publicly traded company on the NASDAQ Global Select Market (INVA). Institutional investors hold a substantial portion of its shares. Major institutional owners include BlackRock, Inc., Vanguard Group Inc, Dimensional Fund Advisors Lp, Renaissance Technologies Llc, Sarissa Capital Management LP, and State Street Corp. Sarissa Capital Management LP is a significant shareholder that has influenced strategic shifts.